Clinical Trial Update: Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating bortezomib in patients with recurrent or refractory extensive-stage small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED